Fig. 8: 4HPAA regulates body weight gain through immune control.
a, Frequencies of B cells, T cells, NK cells, ILCs, macrophages and DCs in the colon of HFD-fed mice with or without 4HPAA treatment in drinking water, measured on day 16. b, Frequencies of ILCs, B cells and T cells in the small intestine of HFD-fed mice treated with or without 4HPAA in drinking water, measured on day 16. c, Rates of body weight gain, measured on week 6, in HFD-fed C57BL/6J wild type (WT), Rag2−/−, Il2rg‒/‒ and Rag2‒/‒Il2rg‒/‒ mice that did or did not receive oral 4HPAA treatment. d, The rate of body weight gain, measured on week 4, in HFD-fed mice treated with IgG2α as a control, or an anti-NK1.1 antibody to deplete NK and ILC1 cells, that did or did not receive oral 4HPAA treatment; n = 5 mice per group. e, The rate of body weight gain, measured on week 6, in NOD-scid (n = 5 mice per group) and M-NSG (n = 6 mice per group) mice fed a HFD that did or did not receive oral 4HPAA treatment. f, The rate of body weight gain, measured on week 6, in BALB/c wild-type (n = 6 mice per group) and Rag2−/−Il2rg−/− (n = 3 mice per group) mice fed a HFD that did or did not receive oral 4HPAA treatment. The percentages of the relative reduction in weight gain between the control and 4HPAA-treated mice are highlighted in red. Data are shown as mean ± s.e.m. Statistical analysis was performed using the two-tailed Mann–Whitney U test. Experiments were independently repeated twice, with similar results.
